Literature DB >> 19273756

Iron accumulation in the substantia nigra of patients with Alzheimer disease and parkinsonism.

Sonia Brar1, David Henderson, John Schenck, Earl A Zimmerman.   

Abstract

BACKGROUND: Preliminary studies have shown an increase in iron accumulation in the substantia nigra but not in the hippocampus in patients with Parkinson disease without dementia and the reverse in patients with Alzheimer disease (AD) and no parkinsonism.
OBJECTIVE: To determine whether iron levels (measured as T2 shortening on magnetic resonance images) are greater in the substantia nigra of patients with AD who have parkinsonism than in those with AD alone.
DESIGN: Case-control study.
SETTING: Albany Medical College, Albany, New York. PARTICIPANTS: Fifteen patients with only AD (controls) and 18 with AD as well as parkinsonism, aged 56 to 89 years, and with a total Clinical Dementia Rating of 5.0 to 11.5. Patients were selected according to the purity of their disease; patients with a Unified Parkinson's Disease Rating Scale motor score of 15 or greater were considered to have parkinsonism. Main Outcome Measure Area under the curve for short T2 (30 milliseconds) in patients with only AD vs patients with AD who developed parkinsonism.
RESULTS: Patients who developed parkinsonism along with their existing dementia had significantly more iron in their substantia nigra than did patients with AD alone (P = .03, 2-sample t test).
CONCLUSIONS: Iron accumulation may be a predictor of parkinsonism. The development of parkinsonism during the course of AD appears to be associated with the accumulation of iron, which in turn may contribute to the pathogenesis of neurologic decline.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19273756     DOI: 10.1001/archneurol.2008.586

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  32 in total

1.  A calorie-restricted diet decreases brain iron accumulation and preserves motor performance in old rhesus monkeys.

Authors:  Erik K Kastman; Auriel A Willette; Christopher L Coe; Barbara B Bendlin; Kris J Kosmatka; Donald G McLaren; Guofan Xu; Elisa Canu; Aaron S Field; Andrew L Alexander; Mary Lou Voytko; T Mark Beasley; Ricki J Colman; Richard H Weindruch; Sterling C Johnson
Journal:  J Neurosci       Date:  2010-06-09       Impact factor: 6.167

Review 2.  Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis.

Authors:  Sharawan Yadav; Anubhuti Dixit; Sonal Agrawal; Ashish Singh; Garima Srivastava; Anand Kumar Singh; Pramod Kumar Srivastava; Om Prakash; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2012-06-27       Impact factor: 5.590

Review 3.  Missing pieces in the Parkinson's disease puzzle.

Authors:  Jose A Obeso; Maria C Rodriguez-Oroz; Christopher G Goetz; Concepcion Marin; Jeffrey H Kordower; Manuel Rodriguez; Etienne C Hirsch; Matthew Farrer; Anthony H V Schapira; Glenda Halliday
Journal:  Nat Med       Date:  2010-05-23       Impact factor: 53.440

4.  Comparison of histological techniques to visualize iron in paraffin-embedded brain tissue of patients with Alzheimer's disease.

Authors:  Sara van Duijn; Rob J A Nabuurs; Sjoerd G van Duinen; Remco Natté
Journal:  J Histochem Cytochem       Date:  2013-07-25       Impact factor: 2.479

Review 5.  Are there common biochemical and molecular mechanisms controlling manganism and parkisonism.

Authors:  Jerome A Roth
Journal:  Neuromolecular Med       Date:  2009-09-16       Impact factor: 3.843

6.  Dopamine D₂/D₃ agonists with potent iron chelation, antioxidant and neuroprotective properties: potential implication in symptomatic and neuroprotective treatment of Parkinson's disease.

Authors:  Sanjib Gogoi; Tamara Antonio; Subramanian Rajagopalan; Maarten Reith; Julie Andersen; Aloke K Dutta
Journal:  ChemMedChem       Date:  2011-05-12       Impact factor: 3.466

7.  High field magnetic resonance microscopy of the human hippocampus in Alzheimer's disease: quantitative imaging and correlation with iron.

Authors:  Vijay Antharam; Joanna F Collingwood; John-Paul Bullivant; Mark R Davidson; Saurav Chandra; Albina Mikhaylova; Mary E Finnegan; Christopher Batich; John R Forder; Jon Dobson
Journal:  Neuroimage       Date:  2011-08-16       Impact factor: 6.556

8.  Parkinsonism with Normal Dopaminergic Presynaptic Terminals in Cerebrotendinous Xanthomatosis.

Authors:  Jun Li; Er-He Xu; Wei Mao; Hong-Wen Qiao; Yong-Tao Zhou; Qi Yang; Shu-Ying Liu; Piu Chan
Journal:  Mov Disord Clin Pract       Date:  2019-10-31

9.  Synthesis and characterization of potential iron-platinum drugs and supplements by laser liquid photolysis.

Authors:  Steven S Nkosi; Bonex W Mwakikunga; Elias Sideras-Haddad; Andrew Forbes
Journal:  Nanotechnol Sci Appl       Date:  2012-06-15

10.  Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.

Authors:  Anthony C Vernon; Saga M Johansson; Michel M Modo
Journal:  BMC Neurosci       Date:  2010-01-05       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.